Cytokinetics | CYTK - Ordinary Share Capital


Cytokinetics reported $124.43M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Amgen USD 541M 1000K Jun/2026
Arca Biopharma USD 50.17M 1.45M Mar/2026
Bayer EUR 982.42M 0 Mar/2026
Biogen USD 146.7M 200K Sep/2025
Brainstorm Cell Therapeutics USD 11.04M 0 Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Capricor Therapeutics USD 57.37M 11.65M Dec/2025
Cytokinetics USD 124.43M 2.17M Mar/2026
Eisai JPY 282.46M 345K Jun/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Exelixis USD 253.7M 8.78M Mar/2026
Geron USD 640.9M 2.54M Mar/2026
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.47B 4.93M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Pfizer USD 5.7B 0 Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.21B 8.25M Mar/2026